Astellas submits application for marketing approval of enzalutamide for prostate cancer

Download PDF Copy

Editorial Checklist

Reviewed

Astellas Pharma US, Inc.May 24 2013

NewsGuard 100/100 Score

Astellas Pharma Inc. (TOKYO: 4503) and Medivation, Inc. (NASDAQ: MDVN) today announced that Astellas has submitted an application for marketing approval of enzalutamide (generic name) to the Ministry of Health, Labour and Welfare in Japan for the treatment of prostate cancer.

Enzalutamide is a novel, once-daily, oral androgen receptor signaling inhibitor. It inhibits multiple steps in the androgen receptor signaling pathway, which has been shown to decrease cancer cell growth and can induce cancer cell death (apoptosis).

This filing application is based mainly on results obtained from the global Phase 3 trial (the AFFIRM trial) and a Phase 1-2 trial conducted in Japan.

Source:

Astellas Pharma US, Inc.

Posted in: Men's Health News | Pharmaceutical News

Tags: Androgen, Anxiety, Apoptosis, Arthralgia, B Cell, Back Pain, Cancer, Cell, Cell Death, Chemotherapy, Diarrhea, Docetaxel, Edema, Headache, Hematuria, Insomnia, Musculoskeletal, Neutropenia, Oncology, Pain, Placebo, Prostate, Prostate Cancer, Receptor, Respiratory, Seizure, Sepsis, Signaling Pathway, T-Cell, Warfarin

Comments (0)

Download PDF Copy

Suggested Reading

Study shows AI can predict prognosis in triple-negative breast cancer

Study shows AI can predict prognosis in triple-negative breast cancer

Adding high-dose IV vitamin C to chemotherapy can boost survival for pancreatic cancer patients

Adding high-dose IV vitamin C to chemotherapy can boost survival for pancreatic cancer patients

Study shows cannabis as a genotoxic substance with cancer risks

Study shows cannabis as a genotoxic substance with cancer risks

Scientists map cancer mutations in EGFR gene, revealing drug resistance paths

Scientists map cancer mutations in EGFR gene, revealing drug resistance paths

Female firefighters face elevated breast cancer risks due to toxic exposures

Female firefighters face elevated breast cancer risks due to toxic exposures

Researchers uncover key genes linked to DCIS progression

Researchers uncover key genes linked to DCIS progression

Air pollution linked to head and neck cancer risk

Air pollution linked to head and neck cancer risk

Neoantigen DNA vaccines improve survival and immunity in triple-negative breast cancer patients

Neoantigen DNA vaccines improve survival and immunity in triple-negative breast cancer patients

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Engineered SNIPRs transform CAR T-cell precision for safer cancer therapy